<?xml version="1.0" encoding="UTF-8"?>
<p>Since ACE2, in addition to expression in lung alveolar epithelium, is also expressed in other organs, such as the intestine, kidney, and heart,
 <xref rid="pvaa053-B31" ref-type="bibr">
  <sup>31</sup>
 </xref> COVID-19 can also cause morbidity and mortality originating from disruptions of these organs. It has been shown that the SARS-CoV-2 infection was related to active myocardial injury, myocardial stress, and cardiomyopathy during the course of illness.
 <xref rid="pvaa053-B32" ref-type="bibr">
  <sup>32</sup>
 </xref> Additionally, âˆ¼25% occurrence of acute kidney injury (AKI) has been reported in several clinical settings.
 <xref rid="pvaa053-B33" ref-type="bibr">
  <sup>33</sup>
 </xref>
 <sup>,</sup>
 <xref rid="pvaa053-B34" ref-type="bibr">
  <sup>34</sup>
 </xref> As regards the higher AngII levels, due to the disrupted ACE2 by the SARS-CoV-2 infection, it was recently shown that this was associated with increased coagulation and fibrinolysis, explaining the observed higher values of D-dimer and cardiovascular thrombotic events.
 <xref rid="pvaa053-B35" ref-type="bibr">
  <sup>35</sup>
 </xref>
</p>
